Clinical bottom line
In patients approaching the end of life, routine artificial hydration does not consistently improve survival or comfort and may increase symptom burden such as edema, respiratory secretions, or nausea. Current evidence supports individualized hydration decisions based on patient symptoms, goals of care, and clinical context rather than routine administration. Clinicians should carefully balance potential benefits and harms, engage in shared decision-making with patients and families, and prioritize symptom control and comfort.
What the evidence shows
Hydration management in end-of-life care remains a complex clinical challenge with limited high-quality randomized data. Systematic reviews and clinical guidelines published in the last five years emphasize that artificial hydration (including intravenous or subcutaneous fluids) does not reliably prolong survival or improve quality of life in terminally ill patients, particularly those with advanced cancer or progressive organ failure [1,2].
A 2017 Cochrane review examining hydration in advanced cancer patients found no significant survival benefit from artificial hydration compared to placebo or no hydration, and inconsistent effects on symptoms such as thirst, fatigue, or delirium [1]. Similarly, a 2020 systematic review of hydration in palliative care highlighted that artificial hydration may exacerbate symptoms like peripheral edema, respiratory secretions, and ascites, potentially worsening patient comfort [2]. However, some patients report subjective relief of thirst or dry mouth with modest hydration, underscoring the importance of symptom-driven care.
Clinical practice guidelines from the European Association for Palliative Care (EAPC) and the National Institute for Health and Care Excellence (NICE) recommend against routine artificial hydration in dying patients but support careful assessment of hydration status and symptom management [3,4]. These guidelines emphasize that hydration decisions should be individualized, considering patient preferences, clinical signs of dehydration, and potential risks such as fluid overload or electrolyte imbalances.
Non-pharmacological measures such as frequent oral care, ice chips, or moistening the lips and mouth are effective first-line interventions for managing thirst and dry mouth symptoms without the risks associated with artificial hydration [2,3]. When artificial hydration is considered, low-volume subcutaneous fluids may be better tolerated than intravenous routes and allow for more gradual fluid administration [4].
Caveats and uncertainty
The evidence base is limited by heterogeneity in patient populations, hydration regimens, and outcome measures. Most studies focus on advanced cancer patients, with less data on non-malignant terminal illnesses such as end-stage organ failure or neurodegenerative diseases. The subjective nature of symptoms like thirst and dry mouth complicates assessment, and placebo effects or caregiver perceptions may influence reported outcomes.
Randomized controlled trials are scarce, and many studies are observational or small-scale, limiting generalizability. The optimal volume, composition, and route of hydration remain unclear, as does the timing of initiation relative to disease trajectory. Ethical considerations and patient or family preferences often influence hydration decisions, introducing potential bias.
Importantly, withholding artificial hydration should not be equated with neglect; rather, it requires proactive symptom management and clear communication. Further research is needed to clarify which subgroups might benefit from hydration and to develop standardized symptom assessment tools.
How this may change practice
Clinicians should adopt a patient-centered approach to hydration at the end of life, prioritizing comfort and symptom relief over routine fluid administration. This involves:
- Assessing symptoms such as thirst, dry mouth, delirium, and edema regularly.
- Employing non-pharmacological oral care measures as first-line interventions.
- Engaging patients and families in shared decision-making about hydration goals and expectations.
- Considering low-volume subcutaneous hydration selectively for symptom control rather than survival extension.
- Monitoring for potential complications of hydration, including fluid overload and electrolyte disturbances.
- Documenting hydration plans clearly in the medical record to guide consistent care.
This evidence supports a shift away from automatic artificial hydration in dying patients and toward individualized, symptom-guided management that respects patient values and clinical context.